Endoca supplies CBD products that have been used successfully in Europe in the treatment of epilepsy and associated neurological disorders.
The Hydroponics Company will make these products available through both the National Access Cannabis (NAC) clinics that it will be establishing, as well as direct order for patients on the Special Access Scheme.
The company recently completed stage I of its R&D and growing facility in Queensland.
Stage I of the development includes greenhouses for indoor cultivation and growth of medicinal cannabis.
Stage II to focus on processing of raw material
Stage II of the company’s growth plan will focus on the processing of raw material into higher value medicinal cannabis oils for use in Australia and overseas.
These products will be provided to approved Australian patients through the NAC clinics in Australia as a branded product.
Medicinal cannabis for Tourette’s Syndrome
BOL Pharma Limited, an Israeli medicinal cannabis company, recently supplied an investigational medicinal product to The Hydroponics Company in the form of a proprietary sublingual tablet.
This is for further research into the potential benefits of medicinal cannabis in Tourette’s Syndrome.
The Hydroponics Company’s subsidiary Canndeo will act on behalf of BOL to facilitate the provision of the investigational product in support of a clinical trial by Wesley Medical Research.
The trial is expected to commence in Q2 2018.